Results 11 to 20 of about 28,066 (219)

PCSK9 is not secreted from mature differentiated intestinal cells

Journal of Lipid Research, 2021
Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes lysosomal degradation of the LDL receptor and is a key regulator of cholesterol metabolism. After the liver, the small intestine is the second organ that highly expresses PCSK9.
Moreau François, Aurélie Thédrez, Damien Garçon, Audrey Ayer, Thibaud Sotin, Wieneke Dijk, Claire Blanchard, Gilliane Chadeuf, Lucie Arnaud, Mikael Croyal, Laurianne Van Landeghem, Melissa Touvron, Xavier Prieur, Anna Roubtsova, Nabil Seidah, Annik Prat, Bertrand Cariou, Cedric Le May   +17 more
doaj   +2 more sources

Regulation of PCSK9 During Oxidized LDL-Induced Foam Cell Formation in RAW264.7 Cells [PDF]

Biology
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is traditionally known for regulating plasma LDL cholesterol levels via LDL receptor degradation.
Md Sariful Islam Howlader, Manjusri Das, Surajit Hansda, Md Afjalus Siraj, Hiranmoy Das   +4 more
doaj   +2 more sources

Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain. [PDF]

PLoS ONE, 2016
PCSK9 is a secreted ligand and negative post-translational regulator of low-density lipoprotein receptor (LDLR) in hepatocytes. Gain-of-function (GOF) or loss-of-function (LOF) mutations in PCSK9 are directly correlated with high or low plasma LDL ...
Steve Poirier, Hocine Ait Hamouda, Louis Villeneuve, Annie Demers, Gaétan Mayer   +4 more
doaj   +2 more sources

Plaque-Hepatic Targeting Nanotherapy Disrupts the PCSK9-LOX-1 Axis to Suppress oxLDL in Atherosclerosis. [PDF]

Adv Sci (Weinh)
Self‑amplifying PCSK9–LOX‑1 feedback axis drives atherosclerotic progression by promoting oxLDL generation and endothelial uptake. A dual‑targeting nanoplatform (siPCSK9@PEAL NPs‑aL) is constructed to simultaneously silence hepatic PCSK9 for lipid lowering and block plaque LOX‑1 for anti‑inflammation.
Duan Y, Qiu Y, Zhu Y, Wang Q, Lin J, Duan Y, Wang Q, Dong Y.   +7 more
europepmc   +2 more sources

PCSK9 Gene Polymorphisms Associated With the Risk of Myocardial Infarction in Iranian Patients [PDF]

International Journal of Basic Science in Medicine, 2021
Introduction: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulatory protein in lipid metabolism and a candidate gene in the etiology of cardiovascular diseases.
Farshad Namordizadeh, Mahboobeh Nasiri
doaj   +1 more source

A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines

Vaccines, 2022
Administration of PCSK9-specific monoclonal antibodies, as well as peptide-based PCSK9 vaccines, can lower plasma LDL cholesterol by blocking PCSK9. However, these treatments also cause an increase in plasma PCSK9 levels, presumably due to the formation ...
Louise Goksøyr, Magdalena Skrzypczak, Maureen Sampson, Morten A. Nielsen, Ali Salanti, Thor G. Theander, Alan T. Remaley, Willem A. De Jongh, Adam F. Sander   +8 more
doaj   +1 more source

PCSK9 is minimally associated with HDL but impairs the anti-atherosclerotic HDL effects on endothelial cell activation

Journal of Lipid Research, 2022
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) regulates the cell-surface localization of LDL receptors in hepatocytes and is associated with LDL and lipoprotein(a) [Lp(a)] uptake, reducing blood concentrations.
Ioannis Dafnis, Aikaterini N. Tsouka, Christina Gkolfinopoulou, Constantinos C. Tellis, Angeliki Chroni, Alexandros D. Tselepis   +5 more
doaj   +1 more source

Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function. [PDF]

PLoS ONE, 2015
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a soluble protein that directs membrane-bound receptors to lysosomes for degradation. In the most studied example of this, PCSK9 binding leads to the degradation of low density lipoprotein receptor
Rachel M DeVay, Lynn Yamamoto, David L Shelton, Hong Liang   +3 more
doaj   +1 more source

PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis

Archives of Medical Science, 2021
Introduction The aim of the study was to study a nanoliposomal anti-PCSK9 vaccine as a novel approach for cholesterol lowering via PCSK9 inhibition. Material and methods An immunogenic peptide construct termed immunogenic fused PCSK9-tetanus (IFPT) was ...
Amir Abbas Momtazi-Borojeni, Mahmoud Reza Jaafari, Mohammad Afshar, Maciej Banach, Amirhossein Sahebkar   +4 more
doaj   +1 more source

Exploring the Pleiotropy of PCSK9: A Wide Range of Influences from Lipid Regulation to Extrahepatic Function [PDF]

Journal of Inflammation Research
Huaru Wang,1 Guodong Tang,2,3 Jianqiang Wu,4 Xuzhen Qin1 1Department of Laboratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People’s Republic of China ...
Wang H, Tang G, Wu J, Qin X
doaj   +1 more source